Prediction of Pain After Breast Cancer Surgery With EEG
TerminatedNCT01392248
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
1. Rationale The inter-individual pain experience immediately after surgery is considerable. In addition, a number of patients develop chronic post surgery pain (CPSP). Patients undergoing surgery for breast cancer are at risk of developing both acute post surgical pain as well as CPSP. Recently, in a group of patients with chronic back pain, it was demonstrated how subjectively reported pain is associated with specific electroencephalography (EEG) parameters, namely the N2 and P3 components of the pain event-related potential (ERP). It was concluded that ERP was associated with self-reported pain in daily life up to two weeks after the measurement. This resulted in the current hypothesis that EEG may be a predictor for postoperative pain. 2. Study design Prospective cohort study. Within 2 weeks before surgery, 150 patients will undergo an EEG measurement with five 'vulnerability' tasks. The experiment will be repeated 6 months postoperatively. Study population: Female patients with breast cancer who will undergo breast surgery, between the ages of 18 to 65 years. 3. Main study parameters/endpoints Primary outcome is postoperative pain, measured in a pain diary 4 days postoperatively. Secondary outcomes are development of chronic post surgery pain and quality of life. The main goal is to develop a comprehensive prediction model for acute and chronic postoperative pain after breast cancer surgery, based on the EEG results of the five vulnerability experiments.
Study details
- Official title
- EEG as a Predictor for Postoperative Pain and the Development of Chronic Postsurgical Pain After Breast Cancer Surgery
- Sponsor
- Maastricht University Medical Center
- Start date
- 2011-07
- Primary completion
- 2012-02
- Sex
- Female
- Age range
- from 18 Years to 65 Years
- Results posted
- No results posted in this snapshot
- Countries
- Netherlands
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Age 18 - 65 years. * ASA 1-2. * Sufficient comprehension of the Dutch spoken and written language. * Elective curative breast cancer surgery, both mastectomy and breast- conserving therapy * Stage I and II breast cancer. * Written informed consent is obtained Exclusion Criteria: * Previous breast surgery, both ipsilateral and contralateral. * Stage III-IV breast cancer. * Chronic pain (\>3months) with an average severity of at least a VAS score 4 during the last two weeks. * Chronic pain for which invasive treatment is needed. * Use of (weak / strong) opioids in the last week. * A history of opioid addiction. * Regular use of the following medications in the last year: antiepileptics,antipsychotics and anxiolytics. * ASA 3 or higher. * Consumption of alcohol (\>4 units) and / or drugs the evening before. * Alcohol consumption (\>= 5 units/day). * Illiteracy, problems with self expression, language barrier. * Serious vision and / or hearing problems, interfering the performance of the experimental tasks. * A history of psychiatric complaints and/or epilepsy . * A medical history of CVA or TIA.
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT01392248